Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Meniere Disease, Ménière
Interventions: Ebselen, Placebo; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Roseville, California + 8 more

Conditions: Critical Limb Ischemia
Interventions: Liposuction, Stem Cell Injection; Procedure · Other
Lead sponsor: Ageless Regenerative Institute; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple System Atrophy
Interventions: TEV-56286, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more

Conditions: Body Fat
Interventions: TempSure; Device
Lead sponsor: Cynosure, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Hunt Valley, Maryland • New York, New York • Rye, New York + 3 more

Conditions: Thyroglossal Duct Cysts
Interventions: Post-surgical drain, No post-surgical drain; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 3 Years to 17 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Hartford, Connecticut • Chicago, Illinois + 2 more

Conditions: Seasonal Allergic Rhinitis
Interventions: STAHIST, Placebo; Drug
Lead sponsor: Magna Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 8
States / cities: Stockbridge, Georgia • South Bend, Indiana • Louisville, Kentucky + 5 more

Conditions: Essential Hypertension
Interventions: Aliskiren, Placebo to Aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Zanesville, Ohio

Conditions: Egg Allergy
Interventions: Trivalent Influenza Vaccine; Biological
Lead sponsor: University of Michigan; Other
Eligibility: 6 Months to 24 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: San Diego, California • Ann Arbor, Michigan • Rochester, Minnesota + 2 more

Conditions: Liver Cancer, Metastatic Cancer
Interventions: cisplatin, doxorubicin, mitomycin, embolization; Drug · Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 37
States / cities: Fort Collins, Colorado • Jacksonville, Florida • Atlanta, Georgia + 18 more

Conditions: Ragweed Allergy
Interventions: Not listed
Lead sponsor: Circassia Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 10
States / cities: Owensboro, Kentucky • Minneapolis, Minnesota • Plymouth, Minnesota + 7 more

Conditions: Spinal Cord Injuries
Interventions: Acute Intermitted Hypoxia, Massed Practise, Rapael Glove; Other · Procedure
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • East Hanover, New Jersey

Conditions: Tumors Metastatic to Brain
Interventions: radiation therapy, thalidomide, quality-of-life assessment; Radiation · Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Brain Tumors, Cancer
Interventions: [18F]fluoro-2-deoxy-D-glucose (FDG), 3'-deoxy-3'-[18F]fluorothymidine (FLT), [15O]-H2O, [11C]Acetate; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Contraception
Interventions: Paragard® T380A Intrauterine Copper Contraceptive with New Inserter; Combination Product
Lead sponsor: CooperSurgical Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 8
States / cities: Denver, Colorado • South Miami, Florida • Atlanta, Georgia + 4 more

Conditions: Atopic Dermatitis
Interventions: 1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2; Drug
Lead sponsor: Amytrx Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Cerritos, California • Encino, California • Long Beach, California + 8 more

Conditions: Advanced HR+/HER2- Breast Cancer
Interventions: IEV407, Fulvestrant, Letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: New Haven, Connecticut • Kansas City, Kansas • Dallas, Texas

Conditions: Schizophrenia
Interventions: Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Upland, California

Conditions: Heart Failure
Interventions: V-LAP™ SYSTEM; Device
Lead sponsor: Vectorious Medical Technologies Ltd.; Industry
Eligibility: 22 Years to 88 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Cabazitaxel (XRP6258), Docetaxel (XRP6976), Prednisone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 32
States / cities: Muscle Shoals, Alabama • Anaheim, California • Bakersfield, California + 28 more

Conditions: Healthy Volunteers
Interventions: Balovaptan therapeutic dose Treatment A, Balovaptan supra-therapeutic dose Treatment B, Active control [moxifloxacin] on Day 2 Treatment C, Active control [Moxifloxacin] on Day 15 Treatment D, Placebo for Balovaptan Treatment C, Placebo for Balovaptan Treatment D, Placebo for Moxifloxacin Treatment A, Placebo for Moxifloxacin Treatment B, Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment D, Moxifloxacin Treatment D; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Cancers With HER2 Expression
Interventions: BAY2701439; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more

Conditions: Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD
Interventions: Rencofilstat, Placebo; Drug
Lead sponsor: Hepion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 39
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 33 more

Conditions: Bone Age
Interventions: BoneAgeModel; Device
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 1,903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Stanford, California • New Haven, Connecticut • Boston, Massachusetts + 3 more

Conditions: Dermatitis, Atopic
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 28
States / cities: Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more

Search by objective public record fields.

SPI-1005 for the Treatment of Meniere's Disease

Autologous Adipose-Derived Stromal Cell Delivered Via Intramuscular Injections for the Treatment of Critical Limb Ischemia

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

Multi-Center Pivotal Study of Radiofrequency Device

Assessing Post-operative Outcomes After Children's Sistrunk Procedure With or Without a Drain

Trial of STAHIST in Seasonal Allergic Rhinitis

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

Safe Administration of Flu Vaccine to Egg Allergic Children

Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver

Ragweed Observational Study

A Multi-Center Clinical Trial in Individuals With Spinal Cord Injury

Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases

Multi-Tracer PET Assessment of Primary Brain Tumors

A Study to Assess the Safety of a New Inserter Device for Paragard® (Intrauterine Copper Contraceptive)

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Staccato Loxapine in Agitation (Proof of Concept)

A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lap™ System

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

Validation of an Artificial Intelligence-based Algorithm for Skeletal Age Assessment

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis